Abstract Background Cytochrome P450 (CYP) 3A4 and 3A5 are major isoforms involved in
the metabolism of tacrolimus, with the CYP3A5 gene being more polymorphic. It is …

Background Polymorphisms in genes encoding transport proteins and metabolizing
enzymes involved in tacrolimus (TAC) disposition may be important sources of individual …

It is currently not clear whether the concentration‐time curves of the immunosuppressants
differ with respect to the CYP3A5, MDR1, or MRP2 genotype in dose‐adapted stable kidney …

Among the immunosuppressive drugs currently used in solid-organ transplantation, the
calcineurin inhibitors cyclosporine and tacrolimus, and the mammalian target of rapamycin …

Background: Tacrolimus is established as immunosuppressant after kidney transplantation.
Polymorphism of the cytochrome P450 3A5 (CYP3A5) gene contributes significantly to …

Aims Tacrolimus (TAC) is one of the most successful immunosuppressive drugs in
transplantation. Its pharmacokinetics (PK) and pharmacogenetics (PG) have been …

BACKGROUND AND AIMS: Variability in CYP3A5 expression associated with differences in
tacrolimus bioavailability has been documented. The wild-type allele CYP3A5* 1 expresses …

Tacrolimus is a widely used immunosuppressive drug for preventing the rejection of solid
organ transplants. The efficacy of tacrolimus shows considerable variability, which might be …

Genetic polymorphisms in biotransformation enzyme CYP3A5 (6986G> A, CYP3A5* 3;
14690A> G, CYP3A5* 6) and drug transporter ABCB1 (1236C> T; 2677G> T/A; 3435C> T) …

Cyclosporine A and tacrolimus (Tac) are inmunosuppresive drugs with a narrow therapeutic
range. Underdosing is associated with organ rejection, whereas overdosing could result in …